Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; 18 of the 167 sources its claims cite were checked for support.

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Open access

Abstract

Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease areas. Although the pharmacokinetic profiles of subcutaneous and intravenous formulations differ, subcutaneous administration has proven effective, safe, well-tolerated, generally preferred by patients and healthcare providers and to result in reduced drug delivery-related healthcare costs and resource use. The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from both health-economic and scientific perspectives. The article covers different indications, treatment settings, administration volumes, and injection devices. We focus on biotherapeutics in rheumatoid arthritis (RA), immunoglobulin-replacement therapy in primary immunodeficiency (PI), beta interferons in multiple sclerosis (MS), and monoclonal antibodies (mAbs) in oncology. While most subcutaneous biotherapeutics in RA, PI, and MS are self-administered at home, mAbs for oncology are still only approved for administration in a healthcare setting. Beside concerns around the safety of biotherapeutics in oncology, a key challenge for self-administration in this area is that doses and dosing volumes can be comparatively large; however, this difficulty has recently been overcome to some extent by the development of high-concentration solutions, the use of infusion pumps, and the coadministration of the dispersion enhancer hyaluronidase. Furthermore, given the increasing number of biotherapeutics being considered for combination therapy and the high dosing complexity associated with these, especially when administered intravenously, subcutaneous delivery of fixed-dose combinations might be an alternative that will diminish these burdens on healthcare systems.

Overview

CoChat Summary

TL;DR

Subcutaneous (SC) administration of biotherapeutics is an established, generally safe and effective alternative to intravenous (IV) dosing in rheumatoid arthritis, primary immunodeficiency, multiple sclerosis, and increasingly oncology, with strong patient/healthcare-provider preference and reduced delivery-related costs and resource use. Key remaining challenges include high-volume/high-dose SC delivery, pharmacokinetic differences from IV dosing, immunogenicity/antidrug-antibody questions, and the fact that oncology SC mAbs are still not approved for home or self-administration.

Key findings

  • SC dosing was preferred over IV in key preference studies: in PrefHer, 415/467 patients (88.9%; 95% CI 85.7–91.6; p < 0.0001) preferred SC trastuzumab, and among 235 healthcare professionals, 181 (77.0%; 95% CI 71.1–82.2) were more satisfied with SC administration. In PrefMab, 79–81% of patients preferred SC rituximab at cycle 6 and 77–84% at cycle 8.
  • SC administration reduced administration time and costs: HannaH reported SC trastuzumab injection duration generally 1–5 min (average 3.3 min) versus 30–90 min for IV; PrefHer time-and-motion assessment found SC saved a mean 55 min (range 40–81; p < 0.0001) of patient chair time and a mean 17 min (range 5–28; p < 0.0001) of active HCP time per session. A UK substudy estimated total savings of £111.81 per patient episode (95% CI 100.44–123.56; p < 0.001), or approximately £2012.00 per patient over 18 cycles; a Belgian study estimated €212.93 saved per administration or €3832.74 per treatment cycle.
  • For high-volume SC biologics, hyaluronidase, high-concentration formulations, and infusion pumps facilitate delivery: hyaluronidase-facilitated SC immunoglobulin improved bioavailability by approximately 20% versus SC immunoglobulin alone (AUC ratio 120.4%; 90% CI 115.5–125.5), and SC rituximab reduced infusion time from at least 90 min IV to 6–8 min.
  • Fixed SC dosing is supported by population pharmacokinetic modeling: across 12 mAbs, fixed versus body-size-based dosing gave similar average AUC variability (42.4% vs 44.2%) and Cmax variability (30.1% vs 30.3%); in HannaH and Sabrina, SC trastuzumab and rituximab achieved noninferior Ctrough and efficacy versus IV.

Methods

  • Design: narrative overview/review comparing SC and IV biotherapeutic administration across rheumatoid arthritis, primary immunodeficiency, multiple sclerosis, and oncology; no new primary data are reported.
  • Data/sample: synthesis of published clinical, health-economic, and nonclinical literature, including pivotal trials (HannaH, PrefHer, Sabrina, PrefMab, MabCute), a systematic review/meta-analysis of IVIG versus SCIG, cost-minimization and time-and-motion studies, and regulatory/label information.
  • Main analysis: qualitative narrative synthesis of pharmacokinetics, safety, immunogenicity, patient/HCP preference, and health-economic outcomes; no systematic search strategy or formal meta-analysis is described.

Limitations

  • Stated in the paper: data on infusion-related reactions are still limited, and head-to-head clinical studies with different mAbs are required; clinical data on hyaluronidase’s impact on bioavailability are limited; understanding of how anatomic injection sites affect SC absorption remains limited; future trials are needed to assess whether immunostimulatory therapeutic proteins can be given SC without significant antidrug-antibody formation affecting pharmacokinetics, efficacy, or safety.
  • Evident from the text: as a narrative review, it does not report a systematic search, inclusion criteria, or formal risk-of-bias assessment; many cited economic/time-and-motion findings come from noninterventional, observational, single-country, or small studies (e.g., UK substudy with 24 patient episodes, Belgian study with 130 episodes, Japanese cost study with 24 patients), which limits generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40259-018-0295-0

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Overview of methodologies that can facilitate subcutaneous administration of high-dose biotherapeutics. These different techniques can be used alone or in combination
Fig. 1 Overview of methodologies that can facilitate subcutaneous administration of high-dose biotherapeutics. These different techniques can be used alone or in combinationCC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 8 Not valid · 106 Not checked · 54 Own results and interpretations

122 more claims · 6 with their cited sources checked

Create a free account to see all 181 claims and to verify the 149 references still open.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 90 references

Research works printed but not linked: 1

  1. De Cock E, Pan I, Sandoval M, Millar D, Knoop A. Healthcare professionals’ perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab. In: European breast cancer conference 2014, Glasgow, Abstr. 42

Cited by

See all 447

Metadata

Authors
Bittner, B., Richter, W., & Schmidt, J.
Affiliations
F. Hoffmann-La Roche AG (CH)
Corresponding author
Bittner, Beate
Venue
BioDrugs
Published
2018-07-24
Volume
32
Issue
5
Pages
425-440
ISSN
  • 1172-7039 (ISSN-L)
  • 1173-8804
  • 1179-190X
OpenAlex
W2883052264
Cited by
447
References
90
Citations by year
2026: 68 · 2025: 71 · 2024: 68 · 2023: 68 · 2022: 63 · 2021: 51 · 2020: 39 · 2019: 17 · 2018: 1
FWCI
2.76
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0 (tdm)
Locations
  • BioDrugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
subcutaneous administration, biologic therapy, intravenous administration, pharmacokinetics, rheumatoid arthritis, primary immunodeficiency, immunoglobulin replacement therapy, multiple sclerosis, interferon-beta, monoclonal antibodies, self-administration, injection device, hyaluronidase, high-concentration solutions, infusion pumps, fixed-dose combination, health economics, health care costs
MeSH terms
Trastuzumab, Antibodies, Monoclonal, Arthritis, Rheumatoid, Biological Availability, Biological Products, Humans, Immunologic Deficiency Syndromes, Injections, Subcutaneous, Multiple Sclerosis, Neoplasms, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. https://app.cochat.ai/papers/10.1007/s40259-018-0295-0
The paper
Bittner, B., Richter, W., & Schmidt, J. (2018). Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs. https://doi.org/10.1007/s40259-018-0295-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.